Zacks Research Issues Negative Outlook for PBH Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Investment analysts at Zacks Research reduced their Q2 2026 earnings estimates for shares of Prestige Consumer Healthcare in a research report issued to clients and investors on Tuesday, January 14th. Zacks Research analyst R. Department now expects that the company will post earnings of $1.18 per share for the quarter, down from their previous estimate of $1.19. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q3 2026 earnings at $1.24 EPS and Q3 2027 earnings at $1.30 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. Prestige Consumer Healthcare’s revenue was down .9% on a year-over-year basis. During the same period in the previous year, the business posted $1.07 EPS.

A number of other research firms have also recently weighed in on PBH. Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. DA Davidson reiterated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Jefferies Financial Group restated a “hold” rating and issued a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a report on Tuesday, September 24th. StockNews.com downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a research note on Monday, December 9th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $85.25.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $78.58 on Friday. Prestige Consumer Healthcare has a 52-week low of $58.22 and a 52-week high of $86.36. The business has a fifty day moving average of $80.52 and a two-hundred day moving average of $74.53. The stock has a market cap of $3.88 billion, a price-to-earnings ratio of 19.12, a price-to-earnings-growth ratio of 2.08 and a beta of 0.51. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quest Partners LLC lifted its position in shares of Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after purchasing an additional 424 shares during the last quarter. Envestnet Asset Management Inc. lifted its holdings in Prestige Consumer Healthcare by 14.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 67,814 shares of the company’s stock worth $4,669,000 after buying an additional 8,782 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Prestige Consumer Healthcare by 4.2% during the 2nd quarter. Renaissance Technologies LLC now owns 373,802 shares of the company’s stock worth $25,736,000 after acquiring an additional 15,100 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in shares of Prestige Consumer Healthcare by 6.7% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 5,969 shares of the company’s stock valued at $411,000 after acquiring an additional 374 shares during the last quarter. Finally, Blair William & Co. IL raised its position in shares of Prestige Consumer Healthcare by 4.4% during the 2nd quarter. Blair William & Co. IL now owns 84,477 shares of the company’s stock worth $5,816,000 after acquiring an additional 3,594 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of the company’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total transaction of $735,585.95. Following the sale, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,810 shares of company stock valued at $3,187,300 in the last ninety days. Company insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.